SANUWAVE Health Inc. (SNWV), a provider of next-generation FDA-approved wound care products, is slated to release its full Q1 results on or around May 9, 2025.
The company's lead product, the UltraMIST Therapy System, has received FDA approval for a range of wound types, including diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. In 2024, SANUWAVE sold 374 UltraMIST systems compared to 211 in the prior year.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com